A multi-center prospective randomized phase III trial to determine the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in nasopharyngeal carcinoma patients with residual EBV [Epstein-Barr virus] DNA following primary radiotherapy with or without concurrent cisplatin

Trial Profile

A multi-center prospective randomized phase III trial to determine the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in nasopharyngeal carcinoma patients with residual EBV [Epstein-Barr virus] DNA following primary radiotherapy with or without concurrent cisplatin

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Cisplatin
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 28 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 28 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top